TLDR BlackRock’s IBIT recorded $25B in ETF inflows in 2025 despite a 9.6% BTC decline. IBIT was the only top 25 ETF by inflows in 2025 to post a negative returnTLDR BlackRock’s IBIT recorded $25B in ETF inflows in 2025 despite a 9.6% BTC decline. IBIT was the only top 25 ETF by inflows in 2025 to post a negative return

BlackRock’s IBIT Attracts Billions, Even With Bitcoin’s Yearly Decline

2025/12/21 21:17
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • BlackRock’s IBIT recorded $25B in ETF inflows in 2025 despite a 9.6% BTC decline.
  • IBIT was the only top 25 ETF by inflows in 2025 to post a negative return.
  • IBIT inflows exceeded those of the SPDR Gold ETF, which posted a 65% annual gain.
  • IBIT launched in January 2024 and now ranks among the top US spot Bitcoin ETFs.

Investor demand for Bitcoin exposure through regulated financial products continued to grow in 2025, despite the asset’s price decline. BlackRock’s iShares Bitcoin Trust (IBIT) recorded over $25 billion in net inflows this year, ranking sixth among all U.S. ETFs. Despite Bitcoin’s year-to-date decline of nearly 10%, investors maintained confidence in IBIT, highlighting a shift toward the long-term adoption of Bitcoin as an institutional asset class.

IBIT Outperforms Peer ETFs in Inflows Despite Negative Returns

IBIT’s performance stands out among the top 25 ETFs by inflows in 2025. According to Bloomberg analyst Eric Balchunas, IBIT was the only fund in that group to post a negative return for the year. Still, it surpassed the SPDR Gold ETF (GLD), which gained 65% in 2025 but brought in $20.8 billion—less than IBIT’s $25 billion.

Vanguard’s S&P 500 ETF (VOO) led with $145 billion in inflows, while iShares S&P 100 ETF (OEF) ranked 25th with $10 billion. IBIT’s position in sixth place despite Bitcoin’s 9.6% decline reflects investor interest in long-term exposure rather than short-term gains. This performance signals confidence in Bitcoin’s future, particularly when accessed through a regulated investment vehicle.

Market Behavior Shifts Toward Long-Term Crypto Allocation

Balchunas remarked that IBIT’s inflows, even during a down year for Bitcoin, indicate growing maturity among investors. Rather than chase momentum, many now view Bitcoin as a strategic allocation within diversified portfolios. He noted that these flows resemble behavior more common among long-term holders than speculative traders.

IBIT’s performance suggests that investors increasingly prioritize the ease of access, regulatory oversight, and asset custody that ETFs provide. Launched in January 2024, IBIT has become one of the most popular spots for Bitcoin ETFs in the U.S., drawing attention from both retail and institutional investors seeking regulated exposure.

Bitcoin ETF Growth May Accelerate if Market Rebounds

Analysts believe IBIT’s ability to attract capital during a year of negative returns positions it for greater inflows in future bull cycles. If Bitcoin enters a growth phase, the fund could benefit from its early leadership and broad recognition in the ETF market. BlackRock’s established reputation and distribution network also contribute to the fund’s appeal.

IBIT’s 2025 growth reflects a changing perspective on Bitcoin investment. Instead of short-term trading, investors appear more willing to adopt a long-term view through stable, regulated products. With continued interest in Bitcoin as a portfolio asset, IBIT may remain a leading vehicle for crypto exposure in the years ahead.

The post BlackRock’s IBIT Attracts Billions, Even With Bitcoin’s Yearly Decline appeared first on CoinCentral.

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$68,025.32
$68,025.32$68,025.32
-0.70%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09